NEUROANATOMY OF SOMATOSTATINERGIC SYSTEM
========================================

SOMATOSTATIN PEPTIDES IN THE BRAIN
----------------------------------

Somatostatin~14~ (SRIF, somatotropin release inhibiting factor) was serendipitously discovered in 1972 by Roger Guillemin and colleagues who were aiming to purify and characterize growth hormone (GH)-releasing hormone from sheep hypothalamus ([@B14]). Soon thereafter, an N-terminally extended peptide, SRIF~28~, was purified from the gut. Both peptides, arising from a common propeptide encoded from a single gene, were found in the mammalian nervous system where SRIF~14~ is the predominant form (for review, see [@B43]).

Two brain SRIF-related bioactive peptides have been discovered later. Cortistatin (CST) has been cloned in 1996 ([@B35]) and shares 11 amino acids with SRIF (**Figure [1](#F1){ref-type="fig"}**). CST peptides are predicted to occur as 14-AA or 17-AA short forms in rodents and humans, respectively, and a 29-AA extended form in both species. CST is mainly restricted to the cerebral cortex and the hippocampus in the central nervous system (CNS). CST has been implicated in several brain functions such as learning and memory, regulation of sleep/wakefulness rhythms and it is suspected to have an anticonvulsant activity (for review, see [@B34]). Recently, bioinformatics analyses of evolutionary conserved sequences identified neuronostatin, a 13-AA amidated peptide also encoded by the somatostatin gene. Mostly found in pancreas, spleen, and brain, it is involved in metabolic, cardiovascular, and neuronal functions ([@B139]).

![**Schematic representation of somatostatin-related peptides.** SRIF~14~ and CST~14~ come from two distinct genes but bind the five mammalian sst receptors. Neuronostatin is encoded by the same gene as SRIF but does not bind SRIF receptors; its effects seem mediated through the melanocortin system. r, rat; m, mouse; h, human.](fendo-03-00154-g001){#F1}

Somatostatin induces many transduction mechanisms in transfected systems (for review, see [@B94]; [@B116]), but deciphering the physiological actions of the native receptors *in situ* remains an intense field of study. The last decade showed increasing progress in understanding the role of SRIF in brain functions using molecular, pharmacological, and behavioral approaches. The development of innovative molecular, genetic, and imaging tools now allows to go a step further and to assess the cellular contribution of SRIF-expressing cells in neuronal networks *ex vivo* and soon *in vivo*. In this review we will give an overview of the latest findings concerning SRIF systems in brain, report some recent data concerning their synaptic actions and their physiological roles within the brain, in normal or pathological conditions.

SOMATOSTATINERGIC NETWORKS IN THE BRAIN
---------------------------------------

Somatostatin is ubiquitously expressed in mammalian brain, including humans (**Figure [2A](#F2){ref-type="fig"}**). SRIF-immunoreactivity is found at high level in the mediobasal hypothalamus and median eminence, amygdala, preoptic area, hippocampus, striatum, cerebral cortex, sensory regions, and the brainstem (for review, see [@B43]; [@B181]).

![Schematic representation of somatostatin and cortistatin distribution in the mouse brain. **(B)** Schematic representation of somatostatin receptors distribution in the mouse brain. AcbT, nucleus accumbens; Amb, ambiguous nucleus; AP, anterior pituitary; AOB, accessory olfactory bulb; Amy, amygdala; Arc, arcuate nucleus; BNST, bed nucleus of the stria terminalis; CC, corpus callosum; CPut, caudate putamen; Cx, cortex; DBB, diagonal band of broca; DMH, dorsomedian hypothalamus; DR, dorsal raphe; iC, inferior colliculus; IL, intermediate lobe of the pituitary; Hi, hippocampus; Hpt, hypothalamus; LRN, lateral reticularis nucleus; ME, median eminence; MOB, main olfactory bulb; NL, neural lobe of the pituitary; NTS, nucleus of the solitary tract; OT, olfactory tubercle; PAG, periaqueductal gray; PBo, pre-Bötzinger nucleus; PeV, periventricular nucleus; PVN, paraventricular nucleus; sC, superior colliculus; S, septum; SON, supraoptic nucleus; SN, substantia nigra; Th, thalamus; VMH, ventromedian hypothalamus.](fendo-03-00154-g002){#F2}

Somatostatin peptide colocalizes with gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter and labels mostly non-glutamatergic cells in the brain. In order to target SRIF interneurons *in situ*, most recent studies took advantage of rodent models expressing the green fluorescent protein (GFP) under the control of the GAD67 promoter to visualize GABAergic populations more easily. In the GIN (GFP-expressing inhibitory neurons) strain ([@B117]) nearly all GFP cells stained for SRIF while in the GAD67-GFP strain, SRIF immunohistochemistry labels 37% of total GFP cells ([@B104]). The recent development of specific Cre recombinase and knock-in inducible driver lines for SRIF ([@B166]) opens promising avenues to study SRIF functions at the cellular level combined to optogenetic and imaging tools.

Previous immunohistochemical and tracing studies have identified two main categories of SRIF neurons: those acting locally in a given structure within microcircuits (interneurons) and those projecting to a distant structure (long-projecting neurons). Nevertheless, recent data using GFP transgenic mice revisit previous anatomical records by demonstrating that some formerly called interneurons also belonged to the projecting neurons category. The different kinds of GABAergic interneurons are classified according to their molecular, physiological, and morphological properties. Immunohistochemical characterization of neuronal populations in rat cortex initially stated, based on calcium-binding proteins and peptides expressions that parvalbumin (PV), SRIF, calretinin, and cholecystokinin labeled four main non-overlapping chemical classes of interneurons ([@B187]). However, several studies later reported a significant colocalization of SRIF and calretinin in mouse brain ([@B187]; [@B91]; [@B97]), pointing out species-dependent variations in the repertoire of calcium-binding proteins and neuropeptides. It seems that neuronal populations immunoreactive for calbindin or the neuropeptide Y strongly overlap with the somatostatinergic population in rats whereas calretinin is preferentially coexpressed with SRIF in the mouse.

Recent morphological and electrophysiological studies using GIN mice focused on SRIF-expressing populations in cortical circuits. In mouse cortex, parvalbumin- and SRIF-expressing neurons respectively constitute 40 and 30% of the total GABAergic neurons, calretinin being expressed in 50% of the somatostatinergic population ([@B135]). The remaining cortical inhibitory interneurons, expressing ionotropic serotonergic receptor 5HT3a, include VIP- and NPY-positive subpopulations whose partial colocalization with SRIF has been reported ([@B61]; [@B188]; [@B135]). SRIF-positive interneurons are homogeneously distributed in all cortical layers (2--6), as compared to PV-positive inhibitory interneurons that are concentrated in the upper part of the layer ([@B121]).

The major class of SRIF interneurons, the Martinotti cells, have ascending axons that arborize and spread horizontally in layer 1, targeting the distal dendritic parts of excitatory pyramidal neurons (for review, see [@B181]). Excitatory inputs onto Martinotti cells are generally strongly facilitating, allowing feedback inhibition of the excited pyramidal cell that increases as function of the rate and the duration of the presynaptic discharge ([@B85]; [@B150]). The relative distance between excitatory and interneurons inputs may also impact feedback selectivity and grade, inhibition being stronger for closer inputs. A recent study using a two-photon microscopy approach coupled to uncaged glutamate in cortical slices of GIN mouse mapped the inhibitory network between SRIF-positive interneurons and pyramidal cells at the single-cell resolution ([@B49]). Whatever the pyramidal cell stimulated, it led to a dense innervation of the surrounding somatostatinergic interneurons, with activity related to the proximity of the cells. Notably, this inhibitory connectivity looked unspecific as all inhibitory interneurons were locally connected to every sampled pyramidal cells regardless whether these were connected among themselves or not. This dense circuit and the fact that somatostatinergic neurons electrically communicate via gap junctions ([@B104]; [@B76]) favors the hypothesis that the entire somatostatinergic population belongs to a same inhibitory cortical circuit, contradicting the hypothesis of specific inhibitory cortical subnetworks.

Additional classes of cortical SRIF inhibitory interneurons have been recently described according to their localization, intrinsic firing properties, expression of molecular markers, and connectivity ([@B61]; [@B108]). On one hand, calretinin expression was proposed as a distinctive marker ([@B135]), since its expression is associated to distinct neuronal morphology and connectivity in populations with distinct ontogenic origin ([@B151]; [@B188]). On the other hand, two novel SRIF-positive subtypes were identified after cluster and principal component analysis of a whole range of morphological or electrophysiological parameters ([@B108]). These cell types have some similarities to neurons labeled in a GABAergic-GFP strain distinct from GIN (X94 strain; [@B104]), such as the lack of expression in the layer 1, but they target different cortical layers. Future identification of their respective calcium-binding proteins and neuropeptides repertoire as well as their molecular phenotype will help to conciliate these independent classifications based on morphological and electrophysiological properties.

Somatostatin is found in most sensory systems, i.e., retina ([@B168]; [@B23]). In the olfactory system, SRIF expression has also been described in sparse short-axon cells scattered in the deep part of the granule cell layer (the main site of intrinsic inhibitory neurons; [@B147]; [@B46]) and in the peripheral glomerular layer (which receives sensory inputs) in some species ([@B78]). Recently, a novel type of somatostatinergic interneurons has been described as predominant in the murine olfactory bulb and specific to this species ([@B97]). SRIF-positive somata and dendritic fields are restricted to the layer of the olfactory bulb where intrinsic GABAergic interneurons and bulbar principal cells interact through dendrodendritic reciprocal synapses to initiate local gamma oscillations responsible for odor processing. Electron microscopy evidences suggest that SRIF-positive interneurons also establish reciprocal dendrodendritic synapses with the bulbar principal cells (mitral cells). SRIF-positive neurons have also been described downstream in the olfactory pathway; SRIF interneurons constitute a major GABAergic population in the pars principalis of the anterior olfactory nucleus and in the olfactory tubercle ([@B16]). In both piriform and entorhinal cortices, two cortical structures involved in the processing of odor coding, multipolar SRIF-positive interneurons displaying Martinotti-like morphological and electrical properties are found in the deep ([@B195]; [@B137]; [@B157]) and superficial ([@B137]; [@B159]) layers respectively.

As mentioned before, in addition to the somatostatinergic interneurons acting within microcircuits, long-projecting somatostatinergic cells have been described in several regions ([@B181]). As glutamatergic pyramidal cells projections do, long-range inhibitory connections mediate communication between multiple brain areas. Long-range inhibitory terminals have a larger diameter and a thicker myelin layer than excitatory projection neurons, suggesting that inhibitory signal may precede the arrival of excitation in co-innervated cortical areas ([@B83]). Long-range projecting SRIF-containing neurons are encountered in numerous brain areas (for review, see [@B181]) such as the hippocampus ([@B83]), the cerebral cortex ([@B170]), and the amygdala ([@B107]). For instance, virtually all non-pyramidal neurons in the amygdala that have long-range projecting axons to the basal forebrain in the rat express SRIF ([@B107]). **Figure [3](#F3){ref-type="fig"}** represents the projections of all long-range somatostatinergic interneurons known to date in the brain.

![**Schematic representations of long-range somatostatinergic interneurons in the central nervous system.** **(A)** Telencephalic efferent projections to the rest of the brain. **(B)** Efferent projections arising from the diencephalon and projecting to the telencephalon and the pons. **(C)** Efferent projections arising from the mesencephalon, the medulla oblongata, the pons and the spinal cord. Enteped, entopeduncular; BLA, basolateral amygdala; BNST, bed nucleus of the stria terminalis; CEA, central amygdala; DG, dentate gyrus; DRG, dorsal root ganglia; MPOA, medial preoptic area; NTS, nucleus of the solitary tract; OB, olfactory bulb; PAG, periaqueductal gray; POA, preoptic area; PVN, paraventricular nucleus.](fendo-03-00154-g003){#F3}

SOMATOSTATIN RECEPTORS IN THE CENTRAL NERVOUS SYSTEM
----------------------------------------------------

Autoradiographic studies characterized initially two SRIF binding site according to their affinity for the synthetic agonist octreotide and their pattern of expression. In the early 1990s, five receptors (sst~1-5~) belonging to the G-protein-coupled receptors (GPCRs) family were cloned and characterized from various species. Sequence homology is 39--57% among the five subtypes, each being highly conserved across species. They activate multiple intracellular targets ([@B116]) and display distinct internalization and dimerization properties ([@B28]). Based on structural, pharmacological, and operational features, they are now divided into two groups displaying nanomolar affinity for both SRIF and CST: SRIF-1 (sst~2~, sst~3~, and sst~5~ receptors) and SRIF-2 (sst~1~ and sst~4~ receptors). Figure 2B represents the wide expression of SRIF receptors in the CNS. In contrast to most GPCRs, sst~1-5~ are unique because their gene coding sequence is devoid of introns. However, this does not preclude the generation of spliced variants such as a shorter isoform of mouse sst~2~, named sst~2B~, originating by the excision of a cryptic intronic sequence ([@B172]), and spliced variants of sst~5~ in human and rodents ([@B26]). While some data suggested that CST also acts through the proadrenomedullin receptor MgrX2 or the ghrelin orexigenic peptide receptors, the existence of specific CST receptors has not been demonstrated ([@B149]). Neuronostatin does not bind to SRIF receptors, but some of its effects seem mediated through the central melanocortin system ([@B194]). Recent findings have shown that neuronostatin is involved in regulating depressive behavior and nociception ([@B190],[@B191], [@B192]).

The extended distribution of sst~2~ receptors in the CNS together with studies using subtype selective SRIF analogs in both *in vivo* and *in vitro* experiments, suggested that these subtypes are the major players in the SRIF receptor family. They have broad inhibitory effects in many neuronal networks including cortex, hippocampus, limbic regions, and sensory systems (retina and olfactory system; [@B181]; [@B97]; [@B125]). The sst~1~ receptor may function as an autoreceptor in basal ganglia, hypothalamus, and sensory systems ([@B169]), and in the hippocampus ([@B32]). sst~3~ receptors are localized to mature neuronal cilia in most brain regions ([@B153]), and pharmacological or genetic blockade of sst~3~ have marked behavioral effects ([@B39]). sst~4~ receptors are highly expressed in the olfactory bulb, cortex, and hippocampus, where their role remains to be clarified. In the mouse they modulate epileptic activity, whereas in the rat it seems that this effect is largely related to sst~2~ receptors. Hippocampal sst~4~ have also been involved in cognitive processes ([@B54]; [@B141]), functionally interacting with sst~2~ ([@B38]; [@B53]). sst~5~ receptors mediate regulation of GH release and inhibit cell proliferation by SRIF/CST, mainly through sst~2~/sst~5~ receptors interaction. The detection of functional truncated forms of sst~5~ suggests that they could interfere in and modulate those interactions ([@B26]).

SOMATOSTATINERGIC FUNCTIONS IN THE BRAIN
========================================

NEURONAL ACTIONS OF SRIF
------------------------

### Presynaptic Mechanisms

Somatostatin, like other neuropeptides, can modulate CNS excitability via presynaptic mechanisms ([@B5]). In rat hippocampus and cortex, SRIF induces a presynaptic inhibition of excitatory neurotransmission leading to a decrease in glutamate release and in the amplitude of evoked synaptic responses ([@B79]; [@B10]; [@B162]; [@B63]). The SRIF-induced decrease in glutamate release is explained by an inhibition of excitatory transmission via a G-protein of the Gi/Go family and modulation of calcium channels. Indeed, SRIF selectively inhibits N-type Ca^2+^ channel via the picrotoxin-sensitive G(i)/G(o) protein. Somatostatin can also inhibit N-type Ca^2+^ channels in the dentate gyrus ([@B6]). By these inhibitory effects on excitatory synaptic transmission, SRIF, co-released with GABA on dendritic shafts of principal neurons, increases and prolongs GABA effect. This presynaptic action on Ca^2+^ conductance could explain, at least in part, the inhibitory effect of SRIF on long-term potentiation in the mouse dentate gyrus ([@B6]). Other studies suggest that presynaptic K^+^ channels modulation may also be involved in the SRIF inhibition of excitatory transmission ([@B162]). More precisions on the mechanisms have been given by [@B63], demonstrating on synaptosomal preparations from mouse cerebral cortex that activation of sst~2~ presynaptic receptors may inhibit the cAMP/PKA pathway stimulated by high potassium concentration, leading to a decrease of the evoked glutamate release. If in the hippocampus, cortex and also hypothalamus, the presynaptic effects of SRIF concern almost exclusively the excitatory transmission ([@B119]), SRIF is also able to decrease GABA release in different brain structures, such as the rat basal forebrain ([@B111]), the neostriatum ([@B103]), and the thalamus ([@B99]). In the basal forebrain, SRIF presynaptically inhibits both GABA and glutamate release onto cholinergic neurons in a Ca^2+^-dependent way.

### Postsynaptic Mechanisms

Effects of SRIF on intrinsic neuronal membrane properties are well documented. Somatostatin induces a membrane hyperpolarization resulting from the activation of two distinct K^+^ current, the voltage-sensitive K^+^ current or M-current (*I*~M~; [@B113]; [@B82]), and a voltage-insensitive leak current ([@B146]). In hippocampal CA1 pyramidal neurons, sst~4~ seems to be the receptor subtype that couples to *I*~M~ ([@B124]).

In medium spiny neostriatal neurons, SRIF produces a qualitative change in the firing pattern from a tonic regular to an interrupted "stuttering"-like pattern ([@B52]). These authors demonstrated that SRIF changes the firing pattern via sst~2~-subtype activation, which reduces the small conductance Ca^2+^-activated K^+^ currents (SK-channels) and activates large conductance g(K)Ca^2+^ (GK channels). These results highlight the fact that SRIF is a regulator of cellular function in the striatum. The numerous effects of SRIF on Ca^2+^ and K^+^ channel conductance in different structures are reviewed by [@B23].

A huge amount of literature has tried to define the pharmacological nature of SRIF effects, using agonists and antagonists of SRIF receptors or mice invalidated for receptor subtypes. Results are often controversial and are different in mice and rats ([@B3]). Therefore, the classification of SRIF effects is complex and it is accentuated by the description of functional cooperation between different receptor subtypes sst~2~/sst~3~, sst~2~/sst~4~, sst~3~/sst~4~ ([@B112]; [@B53]; [@B3]). Recent publications suggest that sst~3~ and sst~4~ (but not sst~1~; [@B32]) have potent anticonvulsive properties ([@B3]), and that sst~2~, the major receptor subtype involved in the anticonvulsant effect of SRIF in the hippocampus exerts a functional cooperation with sst~3~/sst~4~. In hippocampus, sst~1~ activation inhibits both NMDA- and AMPA-mediated responses but did not affect the inhibitory transmission ([@B21]).

SRIF-CONTAINING NEURONS ARE INVOLVED IN PHYSIOLOGICAL FUNCTIONS
---------------------------------------------------------------

### Interneurons

A large diversity of inhibitory interneurons is able to exert inhibition on specific compartments of principal cells. Among these populations is the dendrite-targeting SRIF-expressing interneuron located in oriens-lacunosum moleculare of the hippocampus. These SRIF-containing neurons are the only subtype of interneuron that reliably follows synaptic stimulation of the alveus in the theta frequency range via activation of their kainate receptors, suggesting that they play an important role in theta band frequency oscillations ([@B60]). Spontaneous activities of inhibitory interneurons have been characterized and SRIF-containing neurons are described in the cortex and piriform cortex as regular-spiking ([@B86]; [@B157]) or low-threshold spiking neurons ([@B59]), often opposed to the fast spiking PV-containing neurons. In the hippocampus, SRIF neurons are locked to the ascending phase of the theta cycle. However, using an optogenetic inhibition of different populations of interneurons, it was recently demonstrated that silencing SRIF interneurons increases burst firing of pyramidal cells without altering the theta phase of spikes ([@B132]). Applying optogenetic technique to animals trained to run head-fixed on a treadmill belt rich with visual-tactile stimuli, these authors provided evidence that the dendritic (but not somatic) inhibition of pyramidal neurons by SRIF interneurons is critical for controlling spike burst firing during active exploration. They concluded that perisomatic PV-targeting interneurons control the spikes' theta phase while the dendrite-targeting SRIF interneurons control the rate of discharge. This is in agreement with the fact that dendritic but not somatic GABAergic inhibition is decreased in experimental epilepsy ([@B27]). Combining optogenetic stimulation with *in vivo* two-photon imaging in the mouse visual cortex, [@B185] demonstrate that soma-targeting PV neurons regulate the gain of cortical response, while dendritic-targeting SRIF neurons shift response level and alter stimulus selectivity, leaving response gain unaffected.

Another demonstration of the role of SRIF interneurons in cellular function has been given recently ([@B56]). In this study, SRIF neurons recorded in the barrel cortex of awake mice were tonically active during quiet wakefulness but they decreased their firing during whisker sensorimotor processing. This decrease in firing relieves the dendrites of excitatory pyramidal neurons from inhibition.

It is known that inhibitory neurons have diverse roles in physiological and synaptic function, based on their connectivity patterns and intrinsic properties. All the experiments described above demonstrated that SRIF interneurons have a prominent role in the regulation of distal dendrites excitability.

### Long-range Projecting Neurons

The long-range projecting somatostatinergic non-pyramidal cells found in the hippocampus target the medial septum and the medial entorhinal cortex ([@B181]; [@B109]) and more specifically form inhibitory synapses on GABAergic interneurons of these areas. They coordinate activity between distant brain regions, contributing to the generation and the synchronization of rhythmic oscillatory activity in the hippocampus and entorhinal cortex ([@B109]). They are therefore involved in spatial and temporal coding. Interestingly, early-generated GABA-containing hub neurons, dendrite-targeting interneurons, express preferentially SRIF and give long-range projecting neurons ([@B122]). These superconnected hub cells are present early in the developing hippocampus. They develop a widespread axonal arborization and remain into adulthood. They play a key role in the control of the hippocampal giant depolarizing potentials as well as in the modulation of network dynamics. In the other brain areas, the precise contribution of these long-projecting SRIF neurons in the oscillatory activity still needs to be addressed.

### Hypophysiotropic Neurons

Somatotropin release inhibiting factor was initially discovered as a neurohormone that inhibits GH secretion from anterior pituitary somatotroph cells. This function is exerted by hypophysiotropic neurons, located in the anterior periventricular hypothalamic nucleus, which project to the median eminence and release the peptide in the fenestrated capillaries of the hypothalamo--hypophyseal portal vessels; thus directly connecting the brain to the anterior pituitary. SRIF is also a potent inhibitor of many hormonal and exocrine secretions as well as an antiproliferative agent in normal and tumoral tissue ([@B43]). SRIF analogs (octreotide and lanreotide) have potent inhibitory effects on hypersecretion, thereby alleviating the symptoms associated with neuroendocrine tumors. Furthermore, the antitumor potential of octreotide is now well documented. Pasireotide, a long-acting SRIF analog, has the advantage of targeting a wider range of SRIF receptors (subtypes 1, 2, 3, and 5) than the analogs previously used in clinical practice (which preferentially target subtype 2) and has a broader spectrum of activity (for review, see [@B12]).

INVOLVEMENT OF SRIF SYSTEMS IN SENSORY, MOTOR, AND COGNITIVE FUNCTIONS
----------------------------------------------------------------------

Since SRIF systems are widely expressed in CNS, they are involved in numerous functions including nociceptive and vasoconstrictor properties. Here, we will present recent advances about the role of SRIF systems in autonomic responses (digestion, cardiac rate, and respiration) and motor functions as well as cognitive functions such as learning and memory and emotion (for review, see [@B181]).

### Somatostatinergic Involvement in Sensory Functions

***Somatostatin and visual information*.** Somatostatinergic system is expressed in mammalian retina (for review, see [@B168]; [@B22]; [@B24]), where it is suspected to exert multiple actions on neurons and on retinal physiology. SRIF acts as a positive factor in the retina by regulating homeostasis and protecting neurons against damage. Both sst~2~ and sst~5~ somatostatinergic receptors are involved. Indeed, activation of sst~2~ protects the retina from ischemic insults *ex vivo* ([@B105]) and sst~2~ as well as sst~5~ receptor activation protect from excitotoxicity *in vivo* ([@B88]; [@B87]; [@B89]). The severity of angiogenic responses to hypoxia is correlated to the sst~2~ expression level in the retina ([@B29]). Moreover, the sst~2~-preferring agonist octreotide prevents hypoxia-induced VEGF up-regulation ([@B30]).

***Somatostatinergic modulation of olfactory discrimination*.** Recent studies have shown that SRIF modulates olfactory processing in mice ([@B97],[@B98]). In mouse main olfactory bulb, SRIF is mainly concentrated in local GABAergic interneurons synaptically connected to the mitral cells by reciprocal dendrodendritic synapses. When activated by an odor, mitral cells synchronize and generate gamma oscillations of the local field potentials that are involved in olfactory processing. Pharmacological or genetic blockade of sst~2~ transmission in the olfactory bulb of awake animal selectively decreased the gamma oscillations power while pharmacological activation of sst~2~ had opposite effects. These treatments were respectively correlated to either impairment or improvement of odor discrimination performances of the pharmacologically injected animals. Thus, bulbar endogenous SRIF, presumably released from external plexiform layer interneurons, affects gamma oscillations through the dendrodendritic reciprocal synapse and contributes to olfactory processing.

### Involvement of SRIF in Learning and Memory

It has been reported for decades that SRIF plays a role in learning and memory at different stages of information processing. The first studies investigating its role in cognition showed that intracerebroventricular administrations of SRIF improved learning in active avoidance tasks ([@B11]; [@B174]; [@B176]) and prevented electroshock-induced amnesia in passive avoidance paradigms ([@B174], [@B175]). Conversely, the depletion of SRIF in the brain by cysteamine (which depletes SRIF levels; [@B158]) produced major memory deficits in passive avoidance ([@B4]; [@B143]; [@B36]). These studies revealed that SRIF is involved in the acquisition of information but other studies showed that cysteamine produced memory deficits not only when given before the training session but also within a critical time window (0--4 h) after acquisition, suggesting that SRIF plays a critical role in memory consolidation proces-sing ([@B70], [@B69]; [@B143]; [@B173]).

The hippocampus is an essential structure in learning and memory ([@B81]), and is also a chosen site to study the effects of SRIF on learning and memory since injection of cysteamine impairs tasks requiring its integrity ([@B36]; [@B66]). Surprisingly in the rodent hippocampus, both activation of SRIF receptors as well as depletion of SRIF contents generate hippocampal memory impairments. Indeed, microinjections of cysteamine, SRIF or CST directly into the hippocampus impaired hippocampal-dependent spatial learning ([@B65]; [@B140]; [@B95]; [@B110]; [@B54]). Consistent with these pharmacological results, transgenic mice overexpressing CST display a profound impairment of spatial learning ([@B160]). Studies that investigated which SRIF receptor mediates SRIF memory effect showed that intra-hippocampal injections of the sst~4~ agonist, but not sst~1~, sst~2~, or sst~3~ agonists, dramatically impaired spatial memory formation ([@B54]). Importantly, these authors found that concomitantly to the impairment of spatial memory, an sst~4~ agonist also enhanced the use of striatum-dependent memory. Therefore, it was hypothesized that hippocampal sst~4~ controls the use of cognitive strategies by switching from hippocampus-based multiple associations to simple striatum-based behavioral response through a functional interaction with sst~2~ receptor ([@B53]). The precise cellular and molecular mechanisms involved in this functional interaction between sst~2~ and sst~4~ are not fully understood but some studies showed that sst~4~ mediates increases in glutamatergic excitability and bursting frequency, which were blocked by sst~2~ agonists or antagonists and were lacking in sst~2~ knockout (KO) mice ([@B112]; [@B19]). Therefore, sst~4~ is not the unique SRIF receptor in the hippocampus mediating SRIF memory effects as sst~2~ also modulates memory as previously suggested by [@B38].

### Involvement of SRIF in the Control of Emotion

Somatostatin and its receptors are strongly expressed in the different nuclei of the amygdala ([@B68]), a key brain structure involved in the emotional assessment of the environment ([@B144]). Despite the extensive expression of SRIF systems in this area, the effects of SRIF on emotions have not yet been studied extensively. Nevertheless, some studies reported an involvement of SRIF systems in the control of emotion and anxiety. Indeed, a very recent work revealed that the pattern of activation of SRIF-positive interneurons was specific to the nuclei of the amygdala considered and also to the kind of stressor used ([@B18]). Moreover, SRIF has anxiolytic- and antidepressant-like effects ([@B41]) that are associated with the suppression of the frequency of hippocampal theta activity, a neurophysiological signature common to most classes of anxiolytic drugs (i.e., benzodiazepines, selective 5-HT reuptake inhibitors, 5-HT1A agonists). These effects seem to be mediated by sst~2~ receptor since both intra-septal and intra-amygdala SRIF microinfusions induced anxiolytic effects that were completely reversed by selective sst~2~ receptor antagonist injection in these brain areas ([@B193]). Additional evidence for a specific role of sst~2~ receptor came from the observation that a stressful experience is associated with an increase of sst~2~ mRNA levels within the amygdala ([@B114]) and that mice lacking sst~2~ receptor display increased anxiety-like behaviors associated with increased pituitary ACTH levels, a main regulator of the stress response ([@B182]).

### Involvement of SRIF in Locomotion

An involvement for SRIF was also reported in motor functions. Increased motor activity was shown in rats receiving intracerebroventricular administration of SRIF ([@B74]) as well as in mice receiving unilateral striatal infusions of the peptide by retrodialysis ([@B73]) and in animals receiving direct injections of SRIF in the nucleus accumbens ([@B129]). [@B167] showed that SRIF modulated locomotor activity in biphasic manner. Indeed, shortly after SRIF striatal injection a decrease of locomotor activity is observed whereas later, the locomotor behavior is increased. Similar effects have been found after striatal injection of sst~2~ and sst~4~ agonists. On the other hand, genetic invalidation of sst~2~ receptor in two different strains of mice as well as SRIF null mice showed an impairment of motor functions ([@B182]; [@B197]; [@B1]). But the role of SRIF in locomotion seems to be limited to fine motor control since these different lines of transgenic mice only develop impaired motor coordination in tasks that require a fine motor control and display normal levels of motor activity and coordination in undemanding tasks ([@B182]; [@B197]; [@B1]).

### Autonomic Responses

Somatotropin release inhibiting factor and its receptors are found in several medulla oblongata nuclei that control autonomic functions such as digestion, cardiac rate, and respiration ([@B101]; [@B152]; [@B181]). In the preBötzinger complex (preBötC), a critical component of the respiratory rhythm generator that underlies mammalian breathing, SRIF is expressed in a subpopulation of glutamatergic neurokinin 1 receptor-positive neurons, a kind of neuron rhythmically active ([@B155]). Originating from the homeogene Dbx1 lineage, these cells are mandatory for breathing, since invalidation of the Dbx1 gene impaired their differentiation and disrupted respiratory rhythm generation in the preBötC ([@B13]; [@B62]). Acute silencing of somatostatinergic preBötC neurons increased respiratory rhythm, leading to persistent apnea ([@B164]). Similar effects were found *in vitro* after pharmacological blockade of sst~2~ transmission, while exogenous SRIF application decreased rhythms generation ([@B118]; [@B126]). This demonstrated that the peptide exerts a tonic inhibitory control on the rythmogenic neurons in order to avoid deleterious overactivity, probably through cellular subdomain-specific inhibitory and excitatory synaptic contacts ([@B184]). The existence of long-range somatostatinergic projections to either contralateral PreBötC ([@B155]) or downstream premotor neurons ([@B165]) favors a neuromodulatory role for PreBötC SRIF ([@B101]), whose developmental impairment may be involved in human pathologies ([@B145]) such as the sudden infant death syndrome ([@B96]).

SOMATOSTATINERGIC NETWORKS IN PATHOLOGICAL CONDITIONS
=====================================================

In animals, an alteration of SRIF systems is observed during normal aging ([@B154]) and pathological models of aging. In human a similar specific dysregulation is observed in normal pathological disorders such as some neurodegenerative and psychiatric diseases ([@B58]; [@B57]).

ALZHEIMER'S DISEASE
-------------------

Somatostatin has been involved in Alzheimer's disease (AD) pathology for a number of years. Indeed, since the early 1980s, it is known that SRIF levels in cortex and hippocampus are decreased in AD patients ([@B31]). Later, it was demonstrated that the decline in SRIF concentrations in the CSF ([@B163]) or in the middle frontal gyrus ([@B37]) correlates with cognitive deficits. Using quantitative real-time PCR, a recent study confirmed this decrease of SRIF in the inferior, medial, and superior temporal lobe of AD patients ([@B51]). Interestingly, SRIF concentrations were reported to be significantly lower in Alzheimer patients carrying the epsilon 4 allele of APOE ([@B64]), the main genetic risk factor described to date for late-onset AD ([@B55]). In addition, two different studies found in Finnish and Chinese patients that polymorphisms in the SST gene are associated with the risk of developing AD ([@B177]; [@B189]).

Regarding SRIF receptors, data are limited and controversial. Although all studies agreed on a decrease of SRIF receptors in AD, controversies appeared about the proportion, the localization, and receptor subtype specificity of this decrease. SRIF receptor quantification using quantitative real-time PCR in AD temporal lobe showed a decrease of sst~1~, sst~3~, and sst~4~ receptors whereas sst~2~ and sst~5~ receptors were unchanged ([@B51]). Previously, an immunohistochemistry study reported a similar decrease of sst~4~ but showed a reduction in neuronal sst~5~ -- and a modest decrease in sst~2~ --like immunoreactivity without any changes in sst~1~ immunoreactive neurons ([@B93]). Surprisingly, in the same study, an increase of sst~3~ subtype was observed in AD cortex. A radioligand binding and functional study showed a general receptor decrease in AD brain ([@B7]). More specifically, receptors levels in the frontal and temporal cortex were reduced by approximately 50% of control values in AD patients while a 40% reduction was reported in the hippocampus and no significant changes were found in the cingulate cortex, postcentral gyrus, temporal pole, and superior temporal gyrus. Another radioligand binding study revealed that while the maximal binding capacity of the SRIF-1 receptor subtype (primarily sst~2~, and possibly sst~5~) is altered in frontal and temporal cortices, other putative cortical SRIF receptor classes (SRIF-2 sites, i.e., sst~1~ and sst~4~) are not as broadly affected ([@B92]). Finally, a last study showed a significant decrease only in the frontal cortex, but not in other brain regions ([@B9]). Because of the cholinergic hypothesis regarding AD etiology, it was concluded that the pattern of change of SRIF binding in AD cortex might be secondary to the degeneration of SRIF receptor-bearing cholinergic afferents arising from the nucleus basalis. In line with this idea, experiments in the literature demonstrate that the selective destruction of cholinergic neurons of the basal forebrain with intracerebroventricular injection of 192-IgG saporin produces an irreversible loss of SRIF-immunoreactive neurons in the hilus of the hippocampus ([@B84]) and in the cortex ([@B198]). This last study shows a correlation between the intensity of acetylcholinesterase in the cortex and the number of remaining SRIF cells. These data highlight a trophic dependence of SRIF neurons on cholinergic inputs and are consistent with observations in AD and aging.

Although SRIF deficit is not correlated with the amyloid load in AD brain patients ([@B37]), SRIF was identified as a modulator that increases brain neprilysin activity, one of the main enzymes involved in Aβ degradation ([@B136]). Recently, it has been shown that neuropeptide pituitary adenylate cyclase-activating polypeptide slows down AD-like pathology and improves cognition in a transgenic mouse model of AD through the activation of SRIF-neprilysin cascade ([@B128]). In mouse primary embryonic neurons, SRIF concomitantly increased neprilysin activity and decreased Aβ42 in the culture medium and these effects were blocked by an sst~5~ antagonist (but also an agonist at sst~1~ and sst~3~ receptors; for review, see [@B45]). Moreover, neprilysin activity was decreased by 50% and Aβ42 increased by a similar extent in SRIF KO mice ([@B136]). Such findings may have important implications for understanding the cellular mechanisms leading to AD and suggest that SRIF and its receptors are potential pharmacological targets for AD. Indeed, FK962, which promotes SRIF production in the brain, co-administrated with donepezil, an acetylcholinesterase inhibitor widely used to treat patients, enhances cognition in rat and has been proposed as an add-on therapy for AD ([@B106]). In addition, [@B134] recently suggested that SRIF and CST act as a protective agent against Aβ toxicity. However, in APP transgenic mouse models, data concerning SRIF-containing interneurons are contradictory. In the triple-transgenic model of AD, 3×Tg-AD, inhibitory neurotransmission is unchanged in the cerebral cortex and hippocampus ([@B57]). In a APP/PS1 mouse model of AD, as soon as 6 months of age, a decrease in the number of oriens-lacunosum moleculare hilar perforant path-associated SRIF-positive interneurons was evidenced in the hippocampus, when no change was demonstrated for 21 additional mRNA markers tested ([@B127]). In the APPswe/PS1dE9 mouse model, Aβ deposition disrupted cognitive circuits when the cholinergic and somatostatinergic systems remained relatively intact ([@B142]). Another study on this last model even found that, in most brain regions tested, SRIF concentrations were increased rather than decreased relative to controls ([@B75]). Thus, the validity of a direct and major role for SRIF in the regulation of Aβ42 degradation remains to be further confirmed ([@B80]). More recent studies, focusing on olfaction, an early-altered function in AD ([@B186]), account for evidence of a relationship between Aβ pathology and SRIF alterations in the disease. Indeed, SRIF interneurons and receptors are selectively reduced by approximately 50% in the anterior olfactory nucleus of AD patients ([@B137]). These authors suggested that SRIF decreases in AD might be linked with Aβ. Moreover, an increase in the levels of aggregated Aβ peptide is observed with aging in olfactory cortices of APP/PS1 transgenic mouse model of AD, and it is accompanied by a fall in numbers of SRIF-positive interneurons ([@B138]).

Experiments from our laboratory demonstrated that intrahippocampal injections of Aβ in rats induced aberrant inhibitory septo-hippocampal network activity associated with an impairment of hippocampal memory processes ([@B180]). This effect can be explained by the selective loss of long-range hippocampo-septal projecting neurons population containing calbindin and SRIF ([@B179]). This population of SRIF neurons could be a favored target for Aβ, explaining the early decrease of SRIF observed in AD.

Somatotropin release inhibiting factor is not only interacting with Aβ42 in AD, it has also an effect on Tau phosphorylation. [@B133] indicated that in mouse cortex SRIF and CST induce Tau phosphorylation at Ser262, a site modified in AD ([@B183]), although with different kinetics. An sst~2~/sst~4~ interaction seems implicated in this process but the types of phosphatases that are involved remain to be determined. Moreover, in human apoE4 knock-in mice where Tau phosphorylation and intracellular neurofibrillary tangle-like deposits are detected ([@B77]; [@B71]; [@B15]), Huang's group showed that the number of SRIF-positive interneurons correlated inversely with the performance of these mice in a spatial memory task ([@B2]).

PARKINSON'S DISEASE
-------------------

Alteration of SRIF levels is also observed in other neurodegenerative diseases. Indeed, decrease in SRIF levels has been described in demented Parkinson's disease patients ([@B44]) as well as in a unilateral 6-OHDA experimental mouse model of Parkinson's disease ([@B115]). Recent data obtained in a rat model of Parkinsonism showed that an alteration of presynaptic modulation by SRIF after dopamine deprivation. This observation may underlie a homeostatic mechanism trying to compensate for the excitability imbalance between direct and indirect basal ganglia pathways found during Parkinson's disease ([@B102]).

MAJOR DEPRESSIVE DISORDER
-------------------------

Evidence in major depressive disorder (MDD) suggests an impaired excitation/inhibition balance that is potentially mediated by decreased GABA content ([@B100]). More specifically, [@B148] reported a down-regulation of SRIF in the dorsolateral prefrontal cortex (PFC), the subgenual cingulate cortices ([@B171]), and the amygdala ([@B67]) of MDD patients. [@B40] and [@B42] revealed an antidepressant effect of SRIF mediated by either sst~2~ or sst~3~ receptor and suggested that while SRIF itself is not appropriate for clinical use because of its short half-life and diverse range of effects ([@B123]), a closely related SRIF derivative may have some potential for the pharmacological treatment of depression.

SCHIZOPHRENIA
-------------

One of the most consistent findings in schizophrenia neuropathology is deficits in cortical inhibitory interneurons across multiple cortical regions ([@B72]). It has been known for years that cerebral cortical concentrations of SRIF are reduced in schizophrenics ([@B131]) as well as hippocampal concentration ([@B47]; [@B90]). Moreover, [@B72] found that subjects with schizophrenia exhibited deficits in SRIF expression in the PFC, and this was further confirmed after global analysis from six previously published microarray studies ([@B120]). A recent study suggested that this decrease of SRIF-positive inhibitory interneurons in the PFC may be related to changes in an inflammatory response pathway that are often observed in schizophrenics ([@B48]). In addition, [@B8] showed that SRIF neurotransmission in the PFC of subjects with schizophrenia is also altered at the postsynaptic level in a receptor subtype-, layer-, and cell type-specific manner. The expression of sst~2~, but not sst~1~, mRNA is preferentially lower in layers 5--6, and in larger, putative pyramidal neurons in those layers. These authors suggested converging pre- and postsynaptic mechanisms to reduce inhibitory neurotransmission in pyramidal neurons in the PFC, which could alter the synchronization of low frequency oscillations and disturb working memory performance in subjects with schizophrenia.

EPILEPSY
--------

Somatostatin is highly expressed in brain regions associated with seizures and has been implicated as playing a prominent role in epilepsy ([@B178]) based on the observation of an activity-dependent release of SRIF during seizures, the modulation of SRIF mRNA expression, peptide and receptors levels by seizures and the effect of SRIF and its analogs on seizures ([@B161]; [@B196]). Temporal lobe epilepsy (TLE) is characterized by hippocampal sclerosis together with profound phenotypic changes of different classes of interneurons. Hilar SRIF interneurons undergo extensive degeneration in patients with hippocampal sclerosis ([@B33]; [@B130]). Recently, this selective neurodegeneration has been linked to the specific enrichment of somatostatinergic neurons in striatum-enriched phosphatase, an enzyme that counteracts the MAPK neuroprotective pathway ([@B25]; [@B50]). SRIF receptors may represent potential therapeutic targets for TLE. Indeed, SRIF is released in characteristic conditions of seizures and SRIF and its analogs affect seizures ([@B178]; [@B17]). However, information on the precise contribution of each SRIF receptor on the SRIF-induced inhibition of epileptiform activity is still limited. Although the sst~2~ receptor is likely to mediate the anticonvulsant effects of SRIF in rat hippocampus ([@B178]), observations in the mouse support a central role for sst~4~ ([@B112]) and/or sst~1~ receptors ([@B20], [@B19]) in mediating SRIF inhibition of epileptiform activity. In a rodent model of cortical focal ischemia, sst~2~ is also activated while the infarct size is significantly reduced in sst~2~ KO mice ([@B156]). However, recent data in rats showed that sst~1~ receptors do not appear to mediate the *in vivo* anticonvulsive effect of SRIF ([@B32]), whereas sst~3~ and sst~4~ mediate this effect through a functional interaction with sst~2~ receptor ([@B3]).

CONCLUSION
==========

Somatostatin systems are widely expressed in the different brain regions and are involved in numerous processes from sensory to cognitive functions, suggesting that they play major roles in brain functioning. These key roles are illustrated by the decrease of SRIF concentrations observed in neurodegenerative diseases such as AD and Parkinson's disease but also in psychiatric diseases such as schizophrenia and MDD. From this perspective, SRIF systems represent a potential and challenging therapeutic target. Further studies need to be carried on to unravel the role of SRIF systems in all functions they have been implicated in.
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